Pesquisar
Eupraxia Pharmaceuticals Inc
EPRXAdicionar à lista de desejos
8.580USD
+0.200+2.39%
Fechamento 09-18 16:00（ET）
560.46MValor de mercado
PerdaP/L TTM
Mais detalhes de Eupraxia Pharmaceuticals Inc Empresa
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Eupraxia Pharmaceuticals Inc Perfil
Código da empresaEPRX
Nome da EmpresaEupraxia Pharmaceuticals Inc
Data de listagemMar 09, 2021
CEOHelliwell (James A)
Número de funcionários33
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 09
Endereço201-2067 Cadboro Bay Rd.
CidadeVICTORIA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV8R 5G4
Telefone12505903968
Sitehttps://eupraxiapharma.com/home/default.aspx
Código da empresaEPRX
Data de listagemMar 09, 2021
CEOHelliwell (James A)
Executivos da empresa Eupraxia Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+1.47%
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
100.00K
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
100.00K
--
Ms. Amy Pott
Ms. Amy Pott
Director
Director
--
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Director
Director
--
--
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Director
Director
--
--
Dr. James A. Helliwell, M.D.
Dr. James A. Helliwell, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Richard M. Glickman
Dr. Richard M. Glickman
Independent Director
Independent Director
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+1.47%
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
100.00K
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
100.00K
--
Ms. Amy Pott
Ms. Amy Pott
Director
Director
--
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Director
Director
--
--
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Director
Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Eupraxia Pharmaceuticals Inc?
Os cinco principais acionistas de Eupraxia Pharmaceuticals Inc são: Dr. Michael Wilmink, M.D.
Quantas instituições possuem ações da Eupraxia Pharmaceuticals Inc (EPRX)?
Em 2026Q1, 56 instituições possuíam ações da Eupraxia Pharmaceuticals Inc, com valor de mercado aproximado de 19.60M, representando 32.43% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 818141.00.